key: cord-1027480-3uzb4v9e
authors: Simnica, Donjete; Schultheiß, Christoph; Mohme, Malte; Paschold, Lisa; Willscher, Edith; Fitzek, Antonia; Püschel, Klaus; Matschke, Jakob; Ciesek, Sandra; Sedding, Daniel G; Zhao, Yu; Gagliani, Nicola; Maringer, Yacine; Walz, Juliane S; Heide, Janna; Schulze‐zur‐Wiesch, Julian; Binder, Mascha
title: Landscape of T‐cell repertoires with public COVID‐19‐associated T‐cell receptors in pre‐pandemic risk cohorts
date: 2021-08-28
journal: Clin Transl Immunology
DOI: 10.1002/cti2.1340
sha: b985c66b3a4348eca4edc98d8034e2435cdc244e
doc_id: 1027480
cord_uid: 3uzb4v9e

OBJECTIVES: T cells have an essential role in the antiviral defence. Public T‐cell receptor (TCR) clonotypes are expanded in a substantial proportion of COVID‐19 patients. We set out to exploit their potential use as read‐out for COVID‐19 T‐cell immune responses. METHODS: We searched for COVID‐19‐associated T‐cell clones with public TCRs, as defined by identical complementarity‐determining region 3 (CDR3) beta chain amino acid sequence that can be reproducibly detected in the blood of COVID‐19 patients. Of the different clonotype identification algorithms used in this study, deep sequencing of brain tissue of five patients with fatal COVID‐19 delivered 68 TCR clonotypes with superior representation across 140 immune repertoires of unrelated COVID‐19 patients. RESULTS: Mining of immune repertoires from subjects not previously exposed to the virus showed that these clonotypes can be found in almost 20% of pre‐pandemic immune repertoires of healthy subjects, with lower representation in repertoires from risk groups like individuals above the age of 60 years or patients with cancer. CONCLUSION: Together, our data show that at least a proportion of the SARS‐CoV‐2 T‐cell response is mediated by public TCRs that are present in repertoires of unexposed individuals. The lower representation of these clones in repertoires of risk groups or failure to expand such clones may contribute to more unfavorable clinical COVID‐19 courses.

A betacoronavirustermed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the World Health Organizationhas spread across the world in a pandemic that represents a serious public health concern. 1,2 COVID-19, the illness caused by this new coronavirus, has been recognised as a respiratory disease which, however, can affect multiple organs if early viral clearance cannot be achieved. 3, 4 Adaptive immunity is crucial for viral clearance and is therefore under intensive investigation in COVID-19. 5 The major goals are to understand susceptibility to the virus and immunological determinants of disease severity or fatal outcome. Many of the early studies on the immune response to SARS-CoV-2 have focused on neutralising antibodies. Yet, a growing body of evidence suggests a pivotal role for T cells in viral clearance and in the generation of immunological memory in COVID-19. [6] [7] [8] A few studies have shown that SARS-CoV-2-specific T cells exist in prepandemic T-cell repertoires, 6, [9] [10] [11] [12] [13] [14] but it remains essentially unclear whether the presence of preexisting T cells may explain why some patients remain asymptomatic while others experience severe or even fatal disease courses. Current research suggests that pre-existing T cells may be (at least partially) induced by other 'common cold' coronaviruses. 9, 10, 13 Assuming that these cells have a protective role in COVID-19, this may explain why children and young adults, a part of the population that has more frequent social contacts and therefore potentially higher exposures to other coronavirusesfor example through day care, school and workexperience milder SARS-CoV-2 infections. Yet, we have to acknowledge that our understanding of the role of individual T-cell clonotypesbe it newly generated or selected from the pre-existing repertoirein the potential modulation of COVID-19 severity remains very limited at this point.

Here, we identified a set of public TCR clonotypes that are expanded in a substantial proportion of COVID-19 patients and are of potential use as readout for COVID-19 T-cell immune responses. Moreover, we assessed their representation in prepandemic cohorts with different risk profiles. Using a specific clonotype identification algorithm relying on brain-derived TCRs from patients with fatal COVID-19, we show that public TCRsthat can also be detected in non-exposed individualsare involved in the immune response to this virus. Their lower prevalence in older age and cancer could imply why these risk groups may experience more severe COVID-19 courses.

Identification of a COVID-19-associated public TCR sequence set derived from brains of COVID-19 patients Early in the COVID-19 pandemic, several groups have identified T-cell subsets recognising SARS-CoV-2 epitopes using different TCR peptide affinity measures. 9, 10, 13, 14 However, only few also generated corresponding TCR sequence data 7, 11, 12, 15 and a global COVID-19-associated repertoire has not been defined. To test whether published clonotypes are a shared feature across larger groups of COVID-19 patients, we used the TCR sequence information of 1267 T cells predominantly reactive to the SARS-CoV-2 spike (S) glycoprotein 7, 11, 12, 15 (partially downloaded from vdjdb 16 and McPas-TCR database 17 ) to search for their representation in the peripheral immune repertoires of unrelated COVID-19 patients as well as healthy individuals. We used these 1267 TCR sequences to mine our COVID-19 immune repertoire repository for exact complementaritydetermining region 3 (CDR3) beta amino acid sequence matches. 18 For this analysis, 140 immune repertoires from unrelated COVID-19 patients as well as 140 pre-pandemic age-matched control immune repertoires were retrieved. We found at least one SARS-CoV-2-specific TCR per repertoire (one hit) in 89% of the infected and in 78% of the non-exposed repertoires (Figure 1a ). These data point to a shared S-directed T-cell response between infected individuals that at least partially relies on public TCRs with exact CDR3 identity and confirms, on the repertoire level, previous studies that reported the presence of S-specific CD4 + clones in the blood of 30-80% of non-exposed individuals. 8, 9, 13 Yet, the rather small delta between unexposed and infected individuals was noteworthy and might relate to the observation that, compared to other coronaviruses, SARS-CoV-2 immunodominance is less restricted to the S protein. 9 Thus, we searched for alternative ways to get hold of SARS-CoV-2-associated T-cell clonotypes that distinguish infected from uninfected individuals with higher specificity on the repertoire level. The brain is an organ with physiologically scarce T-cell infiltration. 19 Moreover, previous studies suggest that this organ is affected in the majority of COVID-19 patients. [20] [21] [22] Many patients with mild disease report ageusia and anosmia as one of the most specific symptoms. 23 In addition, the virusand, interestingly, infiltration with cytotoxic T cellshas been detected in the brain of the majority of patients with fatal courses. 21, 22 We, therefore, reasoned that NGS-detectable T cells from brain tissue of patients with fatal COVID-19 may harbour T-cell clonotypes with high specificity for SARS-CoV-2 epitopes. Of 40 brain tissue sections (all major brain parts including the olfactory bulb) from five deceased patients, 30 resulted positive for TRB amplicons. A total of 68 clones could be identified ( Table 1) . As shown in Figure 1b and c, 40% of the independent COVID-19 repertoires encompassed at least one of the brain-derived clonotypes, while this was the case in only 17% of the pre-pandemic age-matched repertoire controls. The degree of sharedness of these clonotypes per se points towards their public nature. We next wished to rule out that the higher frequency of brain-derived clonotypes found in the repertoires of infected individuals was an unspecific consequence of varying repertoire metrics between the COVID-19 and the pre-pandemic control samples. To this end, we retrieved 100x random sets of 68 clonotypes from peripheral blood of healthy individuals and previously published liver biopsies from patients with autoimmune hepatitis, 24 respectively. We searched these in the 140 COVID-19 or prepandemic repertoires. On average, 20% of all repertoires resulted in a hit when queried with sets of blood-derived sequences and close to 0% of repertoires harboured any of the autoimmunerelated clonotypes (Supplementary figure 2) . As opposed to the COVID-19 brain-derived clonotypes, there was no differential enrichment of the blood-derived clonotypes in COVID-19 repertoires (P = 0.1338). Moreover, we normalised all mined repertoires to a similar read depth of 30 000 reads on average and found a similar distribution of brain clone hits (Supplementary figure 3) . These findings argue in favor of the SARS-CoV-2 specificity of the brain-derived clones.

Representation of COVID-19-associated public TCR sequences in COVID-19 patients with different disease severity and after recovery Next, we studied the 68 brain-derived TCR clonotypes in more depth by analysing the number of hits per repertoire which was higher for immune repertoires from COVID-19 patients than for prepandemic healthy repertoires (Figure 1c and d). In addition, we explored their representation across subsets with severe disease reflected by treatment on an intensive care unit (ICU) versus mild-tomoderate disease (non-ICU) as well as after recovery. While the brain-derived clonotypes showed a similar distribution during active infection independent of ICU treatment, their detection was less likely after recovery ( Figure 1e ). Yet, patients previously exposed to the virus showed a higher representation of these sequences in their repertoires as compared to non-exposed individuals, 32-53% vs 17% (Figure 1b and e) .

Since SARS-CoV-2 specificity of our brain-derived T cells could not be directly studied, we asked whether stimulation of peripheral T cells from COVID-19 patients with established sets of 

in the expansion of any of the 68 clonotypes as evidence for epitope specificity. Therefore, we used two different approaches ( Figure 2a ). In approach 1, we aimed for long-term expansion of reactive T cells. In fact, sequencing the T-cell repertoires pre-and post-stimulation of COVID-19 patient HACO-5 revealed expansion of one brain-derived clonotype with the TCRbeta sequence CASSLVGNGYTF after stimulation with SARS-CoV-2 peptides from the set of nucleoprotein epitopes ( Figure 2b ). In the second approach, we sorted activated IFNc-positive T cells from biobanked pre-pandemic blood samples as well as fresh PBMCs of vaccinated healthy individuals and biobanked PBMCs from COVID-19 patients. Overall, we found significant increases of IFNc + CD3 + T cells after 16-h stimulation with SARS-CoV-2 peptide pools ( Figure 2c ). Since pre-pandemic samples had been stored for many years prior to analysis, their background IFNc + level was higher than in the groups with pandemic sampling, but even these samples showed induction of IFNc + CD3 + T cells after stimulation (Figure 2c ). Sequencing the TRB repertoire of sorted IFNc + CD3 + T cells revealed three clonotypes that shared high similarity of the CDR3 beta amino acid sequence with three brainderived clonotypes arguing in favor of their SARS-CoV-2 specificity ( Figure 2c ). Next, we asked whether the designated SARS-CoV-2-specific TCRs could be assigned to a distinct functional T-cell subset in patients with acute infection. To this end, we mined a previously published T-cell single-cell(sc) RNA/V(D)J sequencing dataset 25 consisting of peripheral blood and bronchoalveolar lavage (BAL) fluid samples from 9 patients with COVID-19 as well as 5 control patients with bacterial pneumonia (BAC) for our sequences. Despite the more limited V(D)J sequencing depth of the scRNA assay, which is below the sequencing depth achievable with bulk DNA-based TCR sequencing approaches, we identified two clonotypes from COVID-19 patients with exact CDR3 sequence identity to our brainderived clonotypes (TRBV5-1, TRBJ1-6 CASSLQGYNSPLHF combined with TRAV14/DV4, TRAJ52 CAIVESTTSYGKLT and TRBV29-1, TRBJ2-7 CSVEGGGSYEQYF combined with TRAV8-6, TRAJ6 CAVKSSGGSYIPTF). Since two sequence hits are insufficient to draw conclusions about the cellular identity of the identified public COVID-19 clonotypes, we used the GLIPH2 algorithm to identify TCR sequences that potentially share epitope specificity. 26 This algorithm currently mirrors a state-of-the-art bioinformatical approach to cluster T-cell clones based on shared motifs within the high-probability contact region of the CDR3. For clustering, the 68 brain-derived sequences were either integrated in the COVID-19 oras controlthe BAC scRNA TCRbeta dataset.

All T-cell clusters encompassing at least one public brain-derived TCR sequence were counted (Figure 3a ). This analysis identified 39 individual sequences with high paratope similarity to one of the brain-derived public TCRs in the COVID-19 dataset while in the BAC dataset only three such sequences could be identified. The 39 clonotypes belonged to 11 different TCR clusters (SGS-E, R-GPNTGE, G-AGQET, G-AGQET, SLVG-G, SL-GYNSP, G-SGNT, SL-GGTGE, SLAG-TGE, SR-GYE, R-SNQP, S-RGYE, Figure 3b and Supplementary table 4). We projected all identified clones onto the UMAP R%SNQP   TRBV10−3  TRBV11−2  TRBV12−3  TRBV13  TRBV14  TRBV15  TRBV18  TRBV19  TRBV2  TRBV20−1  TRBV24−1  TRBV25−1  TRBV27  TRBV28  TRBV29−1  TRBV3−1  TRBV30  TRBV5−1  TRBV5−8  TRBV6−1  TRBV6−2  TRBV6−5  TRBV7−2  TRBV7−3  TRBV7−9  TRBV10−3  TRBV11−2  TRBV12−3  TRBV13  TRBV14  TRBV15  TRBV18  TRBV19  TRBV2  TRBV20−1  TRBV24−1  TRBV25−1  TRBV27  TRBV28  TRBV29−1  TRBV3−1  TRBV30  TRBV5−1  TRBV5−8  TRBV6−1  TRBV6−2  TRBV6−5  TRBV7−2  TRBV7−3  TRBV7−9  TRBV10−3  TRBV11−2  TRBV12−3  TRBV13  TRBV14  TRBV15  TRBV18  TRBV19  TRBV2  TRBV20−1  TRBV24−1  TRBV25−1  TRBV27  TRBV28  TRBV29−1  TRBV3−1  TRBV30  TRBV5−1  TRBV5−8  TRBV6−1  TRBV6−2  TRBV6−5  TRBV7−2  TRBV7−3  TRBV7−9   TRBV10−3  TRBV11−2  TRBV12−3  TRBV13  TRBV14  TRBV15  TRBV18  TRBV19  TRBV2  TRBV20−1  TRBV24−1  TRBV25−1  TRBV27  TRBV28  TRBV29−1  TRBV3−1  TRBV30  TRBV5− COVID-19 Bacterial pneumonia Figure 3 . Attribution of cellular phenotype of brain-derived clonotypes and TCR specificity groups using single-cell dataset. (a) Schematic presentation of GLIPH TCR specificity groups formation between clones from single-cell TCR data 25 from patients with COVID-19 or bacterial pneumonia and brain-derived TCR clones (n = 11 and n = 1, respectively). (b) Generation probability (as log 2 ) and TRBV gene usage of clones that form common TCR specificity groups with brain-derived clones. (c) UMAP of CD4 + and CD8 + T single-cell data from 25 with highlighted cells expressing a TCRbeta which is either identical to the brain-derived clones (yellow colour) or belongs to the TCR specificity groups found in (a and b) (red colour = clone was found in blood cells; dark grey = clone was found in bronchoalveolar lavage [BAL] fluid).

plots of the integrated blood and BAL fluid T-cell dataset and found that all of these clones mapped to the peripheral CD4 + T cell pool while no hits were found for CD8 + T cells (Figure 3c ). Of the 39 COVID-19-specific cluster-derived clonotypes, nine were found in the BAL fluid.

To further investigate the cellular identity of these clones, we separately re-clustered all CD4 + COVID-19 cells from the blood and the BAL fluid ( Figure 4a ). In line with the classification by Zhao et al. 25 we identified nine T-cell populations for blood-derived and eight for BAL-derived CD4 + T cells, including Treg (FOXP3), Tr1 (ITGA2, LAG3), Th1 (IFNG), Th17 (RORC, CCR6), CD8 + (CD8A, CD8B) and innate(-like) (NKG7) T-cell subsets (Figure 4a and b) . While most peripheral CD4 + subpopulations contained at least one clusterderived TCR clonotype (Figure 4b) , the majority were part of a na€ ıve CD4 + population expressing elevated levels of the activation markers CD69 and CD38 as well as CCR7 and IFNGR2, but encompassing more cells with reduced CD95 expression (Supplementary figure 3) .

Representation of T cells carrying COVID-19associated public TCR sequences in immune repertoires of individuals not previously exposed to SARS-CoV-2

Presuming that our public COVID-19 TCR clonotypesif present in a pre-infection immune repertoiremay protect from severe disease courses, we asked whether risk groups such as aged individuals or cancer patients showed lower representation of these clonotypes in their repertoires (Figure 5a) . We compared the representation of the 68 TCR clonotypes in individuals < or ≥ 60 years of age using the 140 healthy immune repertoires described above that were acquired prior to the COVID-19 pandemic. Indeed, individuals above 60 years of age showed lower numbers of sequence hits (10.5% vs 19.6%) very likely because of age-dependent repertoire restriction as previously reported 27 (Figure 5b and c). Consistent with this, also the number of sequence hits per repertoire was lower in older individuals than in younger ones (Figure 5d ). Since patients with cancer show diseaseassociated T-cell repertoire restriction, 27 we reasoned that the potentially protective T-cell clonotypes may be less frequently found in repertoires from this group. Indeed, peripheral blood immune repertoires of patients with cancer (222 and 510 repertoires of patients with haematological or solid cancer, respectively, together building a sequence resource of > 35 million TCR reads) were less likely (3.2% and 4.9%) to harbour these sequences compared to healthy old and especially young individuals (Figure 5b and c) . Also, the numbers of hits per repertoire were much lower in patients with cancer than in the healthy controls (Figure 5d) .

Overall, repertoires from unrelated COVID-19 patients with active disease were most likely to harbour one or more of the brain-derived, COVID-19-associated public TCR clonotypes followed by patients after recovery, healthy young and healthy old individuals. SARS-CoV-2 unexposed patients with cancer were least likely to harbour SARS-CoV-2 TCRs in their repertoires.

Adaptive immunity and especially T-cell responses have been recognised as crucial for early control and successful clearance of SARS-CoV-2 infections. 5 However, several important questions remain unanswered including the shape and composition of disease-associated T-cell repertoires across patients, as well as the nature and role of pre-existing T-cell responses for the course and longevity of COVID-19. 28, 29 In the work presented here, we establish a set of TCR clonotypes with public features derived from brain tissue of deceased patients with COVID-19 as immunogenetic markers of SARS-CoV-2-reactive T cells. This set outperformed published clone sets encompassing predominantly S-reactive T cells 7, 11, 12, 15 in the identification of COVID-19associated repertoire imprints. Notably, clones from this set were also found in about 20% of pre-pandemic repertoires of healthy individuals, but with decreasing frequencies in older individuals or patients with cancer. Our data corroborate the notion that certain clonotypes with identical TCRbeta amino acid sequences are relatively common in the general population and might predispose to mild disease courses. 7 Although we did not observe an expansion of these clones in longitudinal samples of patients with active disease, they might offer protection to the host by limiting early viral replication, thus providing a time window to mount a protective immune response. [30] [31] [32] The hypothesis of a pre-existing immune response against SARS-CoV-2 is mainly based on the observation that healthy individuals contain, especially in their peripheral CD4 + compartment, SARS-CoV-2-reactive T cells that potentially represent memory from previous infections with common cold coronaviruses (CCCoVs) able to mediate heterologous immunity. [6] [7] [8] [9] [10] [11] [12] [13] [14] 33 In this line of reasoning, the higher prevalence of these clones in the repertoires of healthy and young individuals may not only rely on higher repertoire diversity and richness in the younger, but also reflect the more intense exposure to CCCoVs in the social environment of people < 60 years of age. However, this model was recently challenged by the findings of Bacher et al. (2020) 12 who showed that CCCoV cross-reactive memory cells are neglectable for pre-existing public T-cell responses Healthy individuals and cancer patients not previously exposed to SARS-CoV-2 (all age groups)

Age-and cancer-related immune repertoire restriction against SARS-CoV-2. In line with our data, this argues for the possibility that fundamental architectural features of the na€ ıve/pre-selection immune repertoire 34, 35 result in the presence of SARS-CoV-2-associated public clonotypes, which act as important modulators of disease severity and determine outcome in COVID-19. As a consequence, the proper composition of a unique pre-infection immune repertoire predisposes to a mild course, while its clonotypic restriction in older individuals or patients with cancer is the mechanistical basis of, or contributes to, the already established risk profiles (e.g. sex or comorbidities) for severe disease courses. 36, 37 Interestingly, a similar age-and risk-dependent pattern was recently described for na€ ıve B cell responses. 38 Although our set does not comprise identical clonotypes shared by a substantial proportion of patients across studies, we found the TCRbeta CASSLVGNGYTF (paired with TCRalpha CVVLRSGNTGKLIF) and the TCRbeta CASRDRVNEQFF (paired with TCRalpha CALNSADRGSTLGRLYF) in the Bacher et al. 12 and Meckiff et al. 11 single-cell datasets, respectively. Of note, the presence and expansion of public clonotypes are not a unique trait of COVID-19, but a common feature of distinct viral infections including EBV, 39 CMV, 40,41 hepatitis C virus 42 and influenza. 43 As suggested by a rhesus macaque model of primary Simian immunodeficiency virus infection, 44 of note, the number of public clonotypes was inversely correlated with viral load pointing towards a protective role of these clonotypes by limiting viral replication.

While these findings argue for a protective role of public T-cell responses in SARS-CoV-2 and other viral infections, they also might have some drawbacks. Numerous reports have associated public responses with autoimmunity in humans and mice, especially after viral infection. 45, 46 This also seems to be the case for SARS-CoV-2 where it has become increasingly clear, that severe cases of COVID-19 often exhibit clinical manifestations of organ-specific or systemic autoimmunity that might persist. 47 Whether public clones contribute to de novo autoimmunity in SARS-CoV-2 infections, or whether hyperinflammation and cellular damage exacerbate existing autoimmunity, especially in the context of distinct HLA genotypes, needs further investigation in the future.

In summary, we identified a set of public clonotypes that allow detection of COVID-19 repertoires with higher specificity as published datasets. These clones exhibit a relatively broad representation in unexposed especially young and healthy individuals. Considering that highthroughput TCR sequencing only captures a very limited proportion of TCR clonotype richness of an individual´s complete TCR repertoire because of limited sampling and sequencing depth, the high prevalence and frequencies of these clones in unexposed repertoires are consistent with recently reported findings. 6, [9] [10] [11] [12] [13] [14] Future prospective studies will have to confirm the predictive potential of public TCRs directed against SARS-CoV-2 epitopes for disease outcome.

Importantly, reliable profiling of immune repertoires can substantially contribute to guide effective countermeasures during newly emerging viral outbreaks, including ways to quickly analyse immune response patterns on a population-wide scale. It is also key for development of effective vaccines or other therapeutic approaches, since immunogenetic analyses, as delineated above, can quickly identify the induction of beneficial or detrimental TCR clusters. 

The brain tissues were derived from five deceased patients with COVID-19 (3 males, 2 females, age 49-87 years). All deceased patients were screened for SARS-CoV-2 virus RNA by throat swab followed by immediate quantitative RT-PCR analysis prior to autopsy. At autopsy, all brains were fixed in buffered 4% formaldehyde, examined macroscopically and subjected to routine neuropathological examination.

Blood samples from 140 COVID-19 patients were analysed; 37 thereof previously immunologically analysed and published by our group. 18 Moreover, we used prepandemic blood samples of 140 age-matched healthy donors and 732 samples of patients with cancer for the data mining analyses. The latter included 222 samples from patients with haematological cancer and 510 samples from patients with solid cancers (sample details can be found in Supplementary table 1).

To determine the entirety of the clonal V(D)J rearrangements of peripheral T-cell receptors (T-cell repertoire), all acquired blood samples underwent nextgeneration sequencing (NGS) of the TRB genetic locus. In brief, genetic loci were amplified together in a multiplex PCR using TRB-A/B primer pools and up to 500 ng of genomic DNA. 48 The primers were purchased from Metabion International AG (Martinsried, Germany). Two consecutive PCRs were performed to generate fragments tagged with Illumina-compatible adapters for hybridisation to the flow cell and 7 nucleotide barcodes for sample identification. All PCRs were performed using Phusion HS II (Thermo Fisher Scientific Inc., Darmstadt, Germany). After gelelectrophoretic separation, amplicons were purified using the NucleoSpin â Gel and PCR Clean-up kit (Macherey-Nagel, D€ uren, Germany), quantified on the Qubit platform (QIAGEN, Hilden, Germany) and pooled to a final concentration of 4 nM. The quality of the amplicon pools was controlled on an Agilent 2100 Bioanalyzer (Agilent Technologies, B€ oblingen, Germany) before undergoing NGS on an Illumina MiSeq (paired-end, 2 9 301-cycles). Samples were sequenced at an average sequencing depth of 56 000 reads (sequencing details can be found in Supplementary table 1). Annotation of TRB loci rearrangements was computed with the MiXCR framework (3.0.8). 49 As reference for sequence alignment, the default MiXCR library was used. Non-productive reads and sequences with less than 2 read counts were not considered for further analysis. Each unique complementarity-determining region 3 (CDR3) nucleotide sequence was defined as one clone. Generation probability of CDR3 sequences was computed using OLGA. 50 All analyses and data plotting were performed using R version 3.6.3.

The 1267 published clonotypes consist of 344 clonotypes from 7 retrieved in January 2021 from VDJdb, 16 40 BAL clonotypes from 15 retrieved in January 2021 from McPAS TCR, 17 530 clonotypes from, 11 dataset after 6-h stimulation and cell count ≥ 10, as well as 353 clonotypes from 12 with cell count ≥ 10 (Supplementary table 2) .

We searched the respective sets of TCR clonotypes based on exact CDR3 beta amino acid sequence identity in a total of 1012 immune repertoires from different cohorts (prepandemic: healthy donors and patients with haematological or solid cancer and pandemic: patients with active COVID-19 or after recovery) using R version 3.6.3.

For our multiple sampling approach, we used the R base command sample with parameter replace = FALSE to create 100 sets of 68 sequences derived from either pool of healthy donor peripheral blood TCR sequences or a pool of liver biopsy TCR from previous work. 24 Bubble plots were computed using R packages packcircles and ggplot2.

T-cell stimulation with SARS-CoV-2-specific peptides Approach 1long-term expansion 15-mer peptides overlapping by ten amino acids corresponding to the amino acid sequence of the first patient diagnosed in Hamburg of the membrane glycoprotein (M) and nucleocapsid phosphoprotein (N) were synthesised 51 (peptides & elephants; Hennigsdorf, Germany) and pooled into 2 pools of 10 peptides (Supplementary table 3) . For T-cell expansion, membrane pool 3 and nucleoprotein pool 3 were used because they have shown the highest antigen-specific T-cell response in a previous study (data not published). 2 9 10 6 frozen PBMCs were divided into 2 wells of a 48-well plate with 500 µL of R10 medium (RPMI 1640 medium with 10% FCS (Sigma-Aldrich), 1% HEPES buffer and 1% penicillin-streptomycin). PBMCs from each well were stimulated with either the membrane or the nucleoprotein pool (Supplementary  table 3 ) at a final concentration of 10 lg mL À1 for 10 days. Medium with recombinant IL-2 (50 U mL À1 ) was added when necessary. 

The GLIPH2 algorithm 26 identifies groups of TCRs that have a high probability of sharing antigen specificity. It clusters TCR clonotypes based on CDR3 sequence similarity according to local motifs (motifs of 2-4 amino acids within high-probability contact region of CDR3) or global similarity (2-4 amino acid differences between two sequences). As input, we used all 68 brain-derived clonotypes together with 49 755 or 24 696 clonotypes from patients with COVID-19 infection or bacterial pneumonia, respectively, 25 to perform GLIPH2 with following parameters: reference version 1.0, reference subset CD4 + and CD8 + and all_aa_interchangeable: yes.

For data analysis and clustering of single-cell data, we used R package seurat (v. 3.2.0), starting with the merged seurat object from previous work 25 comprising only CD3-positive cells from 9 patients with SARS-CoV-2 infection and 5 patients with bacterial pneumonia. Clones were highlighted and plotted into the UMAP using seurat function DimPlot with cells. For further analyses, we subsetted CD4 + cells deriving from SARS-CoV-2 patients' blood and BAL fluid. These two sets were independently reintegrated using function FindIntegrationAnchors and IntegrateData with default parameters. After lognormalisation and scaling, we estimated the dimensionality of the dataset with a principal components analysis (PCA) and elbow plot over the variable features. The majority of robust signals was captured in the first 20 principal components. To cluster the cells, we used FindNeighbors to construct a KNN graph based on Euclidean distance using the dimensions previously defined. Using FindClusters cells were grouped together to graph based clusters. For visualisation, we used UMAP as dimension reduction plot. Clusters were defined according to Zhao et al. 25 and Ciucci et al. 52 (Supplementary figure 2) .

To colour single genes and their expression value in cells, we used function FeaturePlot. We identified differentially expressed genes between all clusters with FindAllMarkers function and calculated the respective mean expression per cluster with AverageExpression. Then, we plotted the expression of the top10 genes per cluster with R package pheatmap. Distribution of the mapped clones over clusters was visualised with a bar plot.

We used t-tests (unpaired two-sided or paired one-sided) to test for statistical significance between two groups and ordinary one-way ANOVA or the chi-square test to compare more than two groups.

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Multiorgan and renal tropism of SARS-CoV-2

SARS-CoV-2 cell tropism and multiorgan infection

Pre-pandemic COVID-19 T-cell repertoires D Simnica et al

Adaptive immunity to SARS-CoV-2 and COVID-19

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Selective and crossreactive SARS-CoV-2 T cell epitopes in unexposed humans

Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4 + T cells in COVID-19

Low-avidity CD4 + T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium

McPAS-TCR: a manually curated catalogue of pathology-associated T cell receptor sequences

Nextgeneration sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease

Understanding the role of T cells in CNS homeostasis

Neuroinvasion of SARS-CoV-2 in human and mouse brain

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions

Self-reported olfactory loss associates with outpatient clinical course in COVID-19

Nextgeneration immunosequencing reveals pathological T cell architecture in autoimmune hepatitis

Clonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lungs of severe COVID-19 patients

Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening

T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors

The known unknowns of T cell immunity to COVID-19

Deciphering the TCR repertoire to solve the COVID-19 mystery

Viral escape mechanisms-escapology taught by viruses

SARS-CoV-2 viral load is associated with increased disease severity and mortality

Avsic-Zupanc T. Viral load and immune response dynamics in patients with haemorrhagic fever with renal syndrome

Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection

Selected before selection: A case for inherent antigen bias in the T cell receptor repertoire

Individual heritable differences result in unique cell lymphocyte receptor repertoires of naive and antigen-experienced cells

COVID-19: risk factors associated with infectivity and severity

Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions

SARS-CoV-2-specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19

Epstein-Barr virus epitope-major histocompatibility complex interaction combined with convergent recombination drives selection of diverse T cell receptor a and b repertoires

Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses

Sequence and structural analyses reveal distinct and highly diverse human CD8 + TCR repertoires to immunodominant viral antigens

Antigen-driven patterns of TCR bias are shared across diverse outcomes of human hepatitis C virus infection

Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8 + T cell epitope

Public clonotype usage identifies protective Gag-specific CD8 + T cell responses in SIV infection

Determinants of public T cell responses

T-cell receptor repertoires share a restricted set of public and abundant CDR3 sequences that are associated with selfrelated immunity

COVID-19 and autoimmune diseases

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations

Concerted Action BMH4-CT98-3936

MiXCR: software for comprehensive adaptive immunity profiling

OLGA: fast computation of generation probabilities of B-and T-cell receptor amino acid sequences and motifs

Complete genome sequence of a SARS-CoV-2 strain isolated in Northern Germany

The emergence and functional fitness of memory CD4 + T cells require the transcription factor Thpok

We thank the following investigators and advisors for contributing patients and samples, technical assistance, supporting laboratory facilities, biobanking, ethical and other input: Jochen Dutzmann, Stephan Eisenmann, Katrin Hoffmann, Kerstin K€ orber-Fehrl, Sebastian Nuding, Marta Siedlecki and Christoph Wosiek. We also thank Dr Alexander Navarrete-Santos, Annika Weißenborn and Dr Dagmar Riemann of the cell sorting core facility at the University Hospital Halle (Saale) for performing the sorting. Moreover, we thank all patients and donors after recovery from COVID-19 for donating their blood for this project. This project was partially funded by the CRC 841 of the German Research Foundation (to MB) as well as by the Martin-Luther-University Halle (Saale).

The authors declare no conflict of interest.

Simnica contributed to conceptualisation; investigation; methodology; resources; visualisation; writing original draft; and writingreview and editing. Christoph Schultheiß contributed to conceptualisation; investigation; methodology; resources; writingoriginal draft; and writingreview and editing. Malte Mohme contributed to conceptualisation; investigation; resources; visualisation; writingoriginal draft; and writingreview and editing. Lisa Paschold contributed to conceptualisation; investigation; methodology; and writingreview and editing. Edith Willscher contributed to data curation; methodology; software; and writingreview and editing. Antonia Fitzek contributed to resources and writingreview and editing. Klaus P€ uschel contributed to resources and writingreview and editing. Jacob Matschke contributed to resources and writingreview and editing. Sandra Ciesek contributed to resources; and writingreview and editing. Daniel G Sedding contributed to resources and writingreview & editing. Yu Zhao contributed to data curation; investigation; software; and writingreview and editing. Nicola Gagliani contributed to investigation and writingreview and editing. Yacine Maringer contributed to methodology and resources. Juliane S Walz contributed to methodology and resources. Janna Heide contributed investigation; methodology; and writingreview and editing. Julian Schulze zur Wiesch conteibuted to investigation and writingreview and editing. Mascha Binder contributed to conceptualisation; funding acquisition; investigation; resources; writingoriginal draft; and writing-review and editing.

COVID-19 patients' repertoire data are available from the iReceptor Public Archive (IPA) as part of the AIRR Data Commons using the iReceptor Gateway (gateway.ireceptor. org; iReceptor Study ID IR-Binder-000001). Moreover, raw fastq sequencing files are deposited in the European Nucleotide Archive (ENA, deposition number PRJEB38339).

Additional supporting information may be found online in the Supporting Information section at the end of the article.This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.